Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 78 of the 79 references it cites were found in a registry or an index; none of the 79 sources its claims cite is checked for support yet.

Moderators of inflammation-related depression: a prospective study of breast cancer survivors

Open access

Abstract

Inflammation has been shown to predict depression, but sensitivity to inflammation varies across individuals. Experimental studies administering potent pro-inflammatory agents have begun to characterize this sensitivity. However, risk factors for inflammation-associated depression in naturalistic contexts have not been determined. The present study examined key psychological and behavioral risk factors (state anxiety, perceived stress, negative affect, disturbed sleep, and childhood adversity) as potential moderators of the relationship between inflammation and depressive symptoms in a prospective longitudinal study of breast cancer survivors. Women with early stage breast cancer were recruited after completing primary cancer treatment (nfinal = 161). Depressive symptoms, inflammatory markers (CRP, IL-6, and sTNF-RII), and key risk factors were assessed post treatment (T1), at 6 and 12-month follow-ups (T2 and T3), and during a final follow-up (TF) 3−6 years after T1; childhood adversity was measured only at T3. Inflammatory markers were combined into a single inflammatory index prior to analyses. Women who reported higher levels of state anxiety, perceived stress, negative affect, and/or sleep disturbance at T1 (post-treatment) exhibited higher depressive symptoms at times when inflammation was higher than typical (interaction βs ranged from .06 to .08; all p s < .014). Results demonstrate the relevance of these risk factors for understanding inflammation-associated depression in a clinical context and could inform targeted strategies for prevention and treatment among at-risk populations.

Overview

CoChat Summary

TL;DR

In a prospective cohort of 161 early-stage breast cancer survivors, post-treatment state anxiety, perceived stress, negative affect, and sleep disturbance moderated the within-person association between inflammation and depressive symptoms over 3–6 years. Childhood adversity did not moderate this association.

Key findings

  • Higher post-treatment (T1) state anxiety, perceived stress, negative affect, and sleep disturbance each strengthened the association between person-centered inflammation and depressive symptoms at any given assessment (interaction βs ranged from .06 to .08; all ps < .014).
  • Simple slopes showed inflammation was positively associated with depressive symptoms among women at high (+1 SD) levels of state anxiety (b = 0.57, p = 0.004), perceived stress (b = 0.70, p < 0.001), negative affect (b = 0.53, p = 0.007), and sleep disturbance (b = 0.54, p = 0.006), but not at low (−1 SD) or average levels.
  • Childhood adversity did not moderate the inflammation–depression association (b = 0.001, β = 0.001, p = 0.94).
  • Secondary analyses found effects were primarily driven by sTNF-RII rather than CRP or IL-6, and interactive effects were significant in women of average age (~51.6 years) or younger (~43.5 years) but non-significant in older (~59.7 years) women.

Methods

  • Secondary analysis of the Mind Body Study, a prospective longitudinal cohort of women with early-stage breast cancer recruited after primary treatment; final analytic sample was 161 women contributing 544 sampling occasions across T1 (post-treatment), T2 (6 months), T3 (12 months), and TF (3–6 years after T1).
  • Inflammatory markers CRP, IL-6, and sTNF-RII were assayed from fasting morning blood samples and combined into a single standardized inflammatory index; depressive symptoms were measured with the BDI-II, and risk factors with STAI, PSS, PANAS negative affect, PSQI, and Risky Families questionnaire (childhood adversity measured only at T3).
  • Primary hypotheses used 2-level robust multilevel models with person-centered inflammation at level 1 and T1 risk factors (or T3 childhood adversity) at level 2, testing inflammation × risk factor interactions and simple slopes at −1 SD, mean, and +1 SD, controlling for age, BMI, race, chemotherapy, radiation, endocrine therapy, cancer stage, and surgery type.

Limitations

  • Stated: the study excluded clinically depressed individuals at recruitment, which may have limited the range of depressive symptoms; it focused on depressive symptoms rather than onset of major depressive disorder; the assessment schedule was not designed to capture acute effects of diagnosis and treatment; the sample was primarily well-educated White breast cancer survivors, limiting generalizability; risk factor measures overlapped with depressive symptom items; and the design does not address temporality or causality.
  • Evident from the text: childhood adversity was measured only at T3, so its lack of moderation may reflect timing or measurement rather than a true absence of effect; the analytic sample was a subset of the parent study and included women more likely to have received endocrine therapy than excluded participants.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41398-021-01744-6

Cites

78 of 78 references verified0 citation errors · 0 not checkable

Statistics

29 tests recomputed · 0 with the reported and recomputed p on opposite sides of .05

Figures

Fig. 1 Study flow chart. A total of 161 participant contributed 544 (151 + 155 + 152 + 86) sampling occasions across the full study period. It should be noted that some participants contributed valid level 1 observations at some time points but not others, and were still in analyses if they contributed at least 2 valid sampling occasions (e.g., missing T1 inflammation and depression data but valid data at T2 and T3). For this reason, the total number of level 2 units (161 participants) is greater than the total number of level 1 units (sampling occasions) at any given time point of the study (151, 155, 152, and 86).
Fig. 1 Study flow chart. A total of 161 participant contributed 544 (151 + 155 + 152 + 86) sampling occasions across the full study period. It should be noted that some participants contributed valid level 1 observations at some time points but not others, and were still in analyses if they contributed at least 2 valid sampling occasions (e.g., missing T1 inflammation and depression data but valid data at T2 and T3). For this reason, the total number of level 2 units (161 participants) is greater than the total number of level 1 units (sampling occasions) at any given time point of the study (151, 155, 152, and 86).CC BY · PubMed Central
Fig. 2 Predicted depressive symptom scores (at any given time) as a function of person-centered inflammation (at any given time) and T1 psychological risk factors (state anxiety, perceived stress, negative affect, and sleep disturbance). Inflammation (as indexed by a composite measure of CRP, IL-6, and sTNF-RII) was positively associated with depressive symptoms at any given time among women who reported high levels of T1 anxiety, perceived stress, negative affect, and sleep disturbance. Predicted depressive symptom scores were adjusted for age, BMI, race, surgery, cancer stage, and receipt of chemotherapy, radiation therapy, and endocrine therapy. Shaded areas depict confidence intervals of simple slopes. The asterisk symbols (*) index statistically significant simple slopes (p < 0.05).
Fig. 2 Predicted depressive symptom scores (at any given time) as a function of person-centered inflammation (at any given time) and T1 psychological risk factors (state anxiety, perceived stress, negative affect, and sleep disturbance). Inflammation (as indexed by a composite measure of CRP, IL-6, and sTNF-RII) was positively associated with depressive symptoms at any given time among women who reported high levels of T1 anxiety, perceived stress, negative affect, and sleep disturbance. Predicted depressive symptom scores were adjusted for age, BMI, race, surgery, cancer stage, and receipt of chemotherapy, radiation therapy, and endocrine therapy. Shaded areas depict confidence intervals of simple slopes. The asterisk symbols (*) index statistically significant simple slopes (p < 0.05).CC BY · PubMed Central

Verification

Claims the paper makes

0 Valid · 0 Not valid · 35 Not checked · 62 Own results and interpretations

49 more claims

Create a free account to see all 97 claims and to verify the 78 references still open.

See all claims — free account
  • It may state two separate claims as one. 19
  • Probably not a substantial claim. 30

Create a free account to see these claims.

Statistics that don’t add up

Each reported p-value recomputed from its test statistic and degrees of freedom.

1 of 1

Statistics recomputed

Every reported test result, recomputed from its test statistic and degrees of freedom. A result shows as not adding up only once an independent check has confirmed it.

  • Doesn’t add upt(389) = 1.65reported p = .09 · recomputed p = .100

    “t(389) = 1.65, p = .09”

  • Consistentχ²(1) = 7.6reported p = .006 · recomputed p = .006

    “X2(1, N = 191) = 7.6, p = .006”

  • Consistentt(442) = 1.5reported p = .13 · recomputed p = .134

    “t(442) = 1.5, p = .13”

  • Consistentt(399) = 1.34reported p = .18 · recomputed p = .181

    “t(399) = 1.34, p = .18”

  • Consistentt(153) = 11.97reported p < .001 · recomputed p < .001

    “t(153) = 11.97, p < .001”

5 of 29 · the rest aren’t loaded

24 more recomputed tests

Create a free account to see every test the Stats check recomputed.

See all tests — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 79 references

Cited by

See all 29

Metadata

Authors
Manigault, A. W., Ganz, P. A., Irwin, M. R., Cole, S. W., Kuhlman, K. R., & Bower, J. E.
Affiliations
University of California, Los Angeles (US)
Corresponding author
Manigault, Andrew W.
Venue
Translational Psychiatry
Published
2021-12-06
Volume
11
Issue
1
Pages
615-615
ISSN
2158-3188 (ISSN-L)
OpenAlex
W4200244638
Cited by
29
References
79
Citations by year
2026: 8 · 2025: 4 · 2024: 3 · 2023: 8 · 2022: 6
FWCI
1.30
Type
journal article
Language
en
Open access
Licence
Locations
  • Translational Psychiatry (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • eScholarship (California Digital Library) (submittedVersion, cc-by)
Funders
  • U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (T32MH015750, K08MH112773)
  • U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01-CA10950)
Topics
  • Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
  • Health Sciences › Medicine › Oncology › Cancer survivorship and care
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Stress, Anesthesia, and Immune Response
Keywords
inflammation, depression, breast cancer survivors, inflammatory markers, C-reactive protein, interleukin-6, soluble TNF receptors, state anxiety, perceived stress, negative affect, sleep disorders, childhood adversity, moderators, inflammatory indices, depressive symptoms
MeSH terms
Cancer Survivors, Breast Neoplasms, Depression, Female, Humans, Inflammation, Longitudinal Studies, Prospective Studies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-11-19, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-19 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Moderators of inflammation-related depression: a prospective study of breast cancer survivors. https://app.cochat.ai/papers/10.1038/s41398-021-01744-6
The paper
Manigault, A. W., Ganz, P. A., Irwin, M. R., Cole, S. W., Kuhlman, K. R., & Bower, J. E. (2021). Moderators of inflammation-related depression: a prospective study of breast cancer survivors. Translational Psychiatry. https://doi.org/10.1038/s41398-021-01744-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.